EVMN
Evommune, Inc.
NYSE: EVMN · HEALTHCARE · BIOTECHNOLOGY
$11.59
+3.02% today
Updated 2026-08-03
Market cap
$409.17M
P/E ratio
—
P/S ratio
40.92x
EPS (TTM)
$-2.12
Dividend yield
—
52W range
$10 – $33
Volume
0.9M
Evommune, Inc. (EVMN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$11.59
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.